SCHEMBL3764646

SCHEMBL3764646

CC1(C)CC(=O)c2sc(N3CCOCC3)c(-c3cccc(C(=O)NCc4ccccc4)c3)c2C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
CNR2 P34972 1/20 0.43
KDM1A O60341 1/20 0.43
HDAC1 Q13547 1/20 0.43
ALDH1A1 P00352 4/20 0.41
CFD P00746 1/20 0.41
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
SCN9A Q15858 1/20 0.39
EPHX2 P34913 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
PIK3CA P42336 1/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39
REN P00797 1/20 0.39
CTSD P07339 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762516 0.93 MEN1 (0.46) MAPK1KDM1AHDAC1MAPTPIK3CA
SCHEMBL3769319 0.92 MAPT (0.48) CNR2KDM1AHDAC1MAPTPIK3CA
SCHEMBL3765560 0.90 BUB1 (0.40) KDM1AHDAC1ALDH1A1MAPTJAK2
SCHEMBL3761666 0.89 KMT2A (0.48) MAPK1KDM1AHDAC1ALDH1A1SCN9A
SCHEMBL3759012 0.88 JAK2 (0.47) KDM1AHDAC1JAK2JAK1TYK2
SCHEMBL3757673 0.87 PIK3CA (0.41) MAPTSCN9APIK3CAHSD17B10
SCHEMBL3759936 0.87 CYP2C19 (0.49) EPHX2
SCHEMBL3763752 0.87 KDM1A (0.39) MAPK1KDM1AHDAC1ALDH1A1MAPT
SCHEMBL3755814 0.86 NPC1 (0.41) MAPK1ALDH1A1MAPTALOX15SCN9A
SCHEMBL3754752 0.86 PRKDC (0.45) ALDH1A1MAPTSCN9APIK3CAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA MAPK1 178/4885CNR2 3147/4885KDM1A 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.